Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16284
Title: Recurrent glioblastoma: current patterns of care in an Australian population
Austin Authors: Parakh, Sagun ;Thursfield, Vicky;Cher, Lawrence M ;Dally, Michael;Drummond, Katharine J;Murphy, Michael;Rosenthal, Mark A;Gan, Hui K 
Affiliation: Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia
Cancer Epidemiology Centre, Cancer Council of Victoria, Melbourne, Victoria, Australia
Alfred Health, Prahran, Melbourne, Victoria, Australia
Department of Neurosurgery, Royal Melbourne Hospital, Parkville, Melbourne, Victoria, Australia
Department of Surgery, Melbourne University, Melbourne, Victoria, Australia
St. Vincent’s Hospital, Fitzroy, Melbourne, Victoria, Australia
Department of Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Grattan Street, Parkville, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Victoria, Australia
School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia
Issue Date: Feb-2016
metadata.dc.date: 2015-11-06
Publication information: Journal of Clinical Neuroscience 2016; 24: 78-82
Abstract: This retrospective population-based survey examined current patterns of care for patients with recurrent glioblastoma (rGBM) who had previously undergone surgery and post-operative therapy at original diagnosis. The patients were identified from the Victorian Cancer Registry (VCR) from 2006 to 2008. Patient demographics, tumour characteristics and oncological management were extracted using a standardised survey by the treating clinicians/VCR staff and results analysed by the VCR. Kaplan–Meier estimates of overall survival (OS) at diagnosis and progression were calculated. A total of 95 patients (48%) received treatment for first recurrence; craniotomy and post-operative treatment (38), craniotomy only (34) and non-surgical treatment (23). Patients receiving treatment at first progression had a higher median OS than those who did not (7 versus 3 months, p < 0.0001). All patients progressed after treatment for first progression with 43 patients (45%) receiving treatment at second progression. To our knowledge this is the first population-based pattern of care survey of treatment for rGBM in an era where post-operative “Stupp” chemo-radiation is standard. First and second line therapy for rGBM is common and associated with significant benefit. Treatment generally includes re-resection and/or systemic therapy.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16284
DOI: 10.1016/j.jocn.2015.08.025
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/26549675
Type: Journal Article
Subjects: Chemotherapy
Recurrent glioblastoma
Survival
Appears in Collections:Journal articles

Show full item record

Page view(s)

6
checked on Dec 2, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.